Dupixent, developed by Regeneron (REGN.US) and Sanofi (SNY.US), has been approved in the EU for the treatment of adult patients with chronic obstructive pulmonary disease.

Dupixent is the first new therapy approved for the treatment of COPD in the European Union for over a decade.

Zhitong Finance08:00

Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,183

Morgan Stanley analyst Terence Flynn maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and maintains the target price at $1,183.According to TipRanks data, the analyst has a success ra

Futu NewsJul 3 21:32 · Ratings

Buy Rating for Regeneron Pharmaceuticals Amidst EU Approval of Dupixent and Positive Market Outlook

TipRanksJul 3 21:25

Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data

On Wednesday, the European Medicines Agency (EMA) approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characteriz

BenzingaJul 3 20:55

Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD

Yahoo FinanceJul 3 20:06

Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) said Wednesday the European Commission has approved Dupixent as an additional maintenance treatment for adults with uncontrolled chronic obstructive p

MT NewswiresJul 3 16:15